English
简体中文
Total: £ 56.28
Published Date: 2026-04-10 | Pages: 114 | Tables: 114 | Pharma & Healthcare
The global Bi-Specific Antibodies Therapy market was valued at US$ 5114 million in 2025 and is anticipated to reach US$ 21860 million by 2032, at a CAGR of 23.4% from 2026 to 2032.
A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.
The growth of the bispecific antibody therapy market is driven by a combination of rising clinical demand, technological advancements, investment momentum, and regulatory support. One of the primary drivers is the increasing global incidence of cancer—particularly hematological malignancies and treatment-resistant solid tumors—which has created a strong demand for more precise and effective immunotherapies. Bispecific antibodies, with their ability to simultaneously target two different antigens, offer enhanced specificity and immune activation, positioning them as a promising next-generation therapeutic approach in oncology.
Advancements in biotechnology and antibody engineering have significantly accelerated the development of bispecific platforms. Historically, challenges such as structural complexity, poor stability, and low manufacturing yield limited their progress. However, breakthroughs in protein design, expression systems, and drug delivery technologies have enabled the emergence of clinically viable formats such as BiTEs (bispecific T-cell engagers), CrossMabs, and DVD-Igs. These innovations have improved manufacturability, stability, and efficacy, paving the way for a broader clinical pipeline.
In parallel, growing investor interest and funding in the biopharmaceutical sector have fueled the expansion of bispecific antibody R\&D. Both established pharmaceutical companies and biotech startups are increasingly investing in this field, supported by active venture capital and strategic partnerships. Regulatory bodies like the FDA and EMA are also showing flexibility in reviewing novel biologics, facilitating faster development timelines and market access for bispecific therapies.
On the patient side, there is increasing acceptance of targeted, personalized treatments that offer superior outcomes compared to traditional therapies. Bispecific antibodies often demonstrate reduced off-target toxicity and enhanced immune-mediated tumor cell killing, further driving clinical adoption.
In summary, the bispecific antibody therapy market is being propelled by unmet clinical needs, technological maturation, strong financial backing, and a favorable regulatory environment—factors that together are shaping a rapidly growing and high-potential therapeutic space.
Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%. North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.
This report delivers a comprehensive overview of the global Bi-Specific Antibodies Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bi-Specific Antibodies Therapy. The Bi-Specific Antibodies Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Bi-Specific Antibodies Therapy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Bi-Specific Antibodies Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.
Segment by Type
Fragment-Based Antibodies
IgG-Based Antibodies
Segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Bi-Specific Antibodies Therapy companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Fragment-Based Antibodies
1.2.3 IgG-Based Antibodies
1.3 Market by Application
1.3.1 Global Bi-Specific Antibodies Therapy Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Cancer
1.3.3 Haemophilia
1.3.4 Other Non-Cancer Diseases
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bi-Specific Antibodies Therapy Market Perspective (2021–2032)
2.2 Global Bi-Specific Antibodies Therapy Growth Trends by Region
2.2.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Bi-Specific Antibodies Therapy Historic Market Size by Region (2021–2026)
2.2.3 Bi-Specific Antibodies Therapy Forecasted Market Size by Region (2027–2032)
2.3 Bi-Specific Antibodies Therapy Market Dynamics
2.3.1 Bi-Specific Antibodies Therapy Industry Trends
2.3.2 Bi-Specific Antibodies Therapy Market Drivers
2.3.3 Bi-Specific Antibodies Therapy Market Challenges
2.3.4 Bi-Specific Antibodies Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue
3.1.1 Global Top Bi-Specific Antibodies Therapy Players by Revenue (2021–2026)
3.1.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Players (2021–2026)
3.2 Global Top Bi-Specific Antibodies Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Bi-Specific Antibodies Therapy Revenue
3.4 Global Bi-Specific Antibodies Therapy Market Concentration Ratio
3.4.1 Global Bi-Specific Antibodies Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bi-Specific Antibodies Therapy Revenue in 2025
3.5 Global Key Players of Bi-Specific Antibodies Therapy Head Offices and Areas Served
3.6 Global Key Players of Bi-Specific Antibodies Therapy, Products and Applications
3.7 Global Key Players of Bi-Specific Antibodies Therapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Bi-Specific Antibodies Therapy Breakdown Data by Type
4.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Type (2021–2026)
4.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (2027–2032)
5 Bi-Specific Antibodies Therapy Breakdown Data by Application
5.1 Global Bi-Specific Antibodies Therapy Historic Market Size by Application (2021–2026)
5.2 Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Bi-Specific Antibodies Therapy Market Size (2021–2032)
6.2 North America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Bi-Specific Antibodies Therapy Market Size by Country (2021–2026)
6.4 North America Bi-Specific Antibodies Therapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bi-Specific Antibodies Therapy Market Size (2021–2032)
7.2 Europe Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Bi-Specific Antibodies Therapy Market Size by Country (2021–2026)
7.4 Europe Bi-Specific Antibodies Therapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size (2021–2032)
8.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2021–2026)
8.4 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Bi-Specific Antibodies Therapy Market Size (2021–2032)
9.2 Latin America Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2021–2026)
9.4 Latin America Bi-Specific Antibodies Therapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bi-Specific Antibodies Therapy Market Size (2021–2032)
10.2 Middle East & Africa Bi-Specific Antibodies Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2021–2026)
10.4 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Bi-Specific Antibodies Therapy Introduction
11.1.4 Roche Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Bi-Specific Antibodies Therapy Introduction
11.2.4 Amgen Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.2.5 Amgen Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Bi-Specific Antibodies Therapy Introduction
11.3.4 Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.3.5 Sanofi Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Bi-Specific Antibodies Therapy Introduction
11.4.4 Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.4.5 Pfizer Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Introduction
11.5.4 Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.5.5 Johnson & Johnson Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Bi-Specific Antibodies Therapy Introduction
11.6.4 AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.6.5 AstraZeneca Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Bi-Specific Antibodies Therapy Introduction
11.7.4 AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.7.5 AbbVie Recent Development
11.8 Lindis Biotech
11.8.1 Lindis Biotech Company Details
11.8.2 Lindis Biotech Business Overview
11.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Introduction
11.8.4 Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.8.5 Lindis Biotech Recent Development
11.9 MacroGenics, Inc
11.9.1 MacroGenics, Inc Company Details
11.9.2 MacroGenics, Inc Business Overview
11.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Introduction
11.9.4 MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.9.5 MacroGenics, Inc Recent Development
11.10 Genmab
11.10.1 Genmab Company Details
11.10.2 Genmab Business Overview
11.10.3 Genmab Bi-Specific Antibodies Therapy Introduction
11.10.4 Genmab Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.10.5 Genmab Recent Development
11.11 Alphamab Co. Ltd
11.11.1 Alphamab Co. Ltd Company Details
11.11.2 Alphamab Co. Ltd Business Overview
11.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Introduction
11.11.4 Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.11.5 Alphamab Co. Ltd Recent Development
11.12 Akeso, Inc.
11.12.1 Akeso, Inc. Company Details
11.12.2 Akeso, Inc. Business Overview
11.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Introduction
11.12.4 Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2021–2026)
11.12.5 Akeso, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Bi-Specific Antibodies Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Fragment-Based Antibodies
Table 3. Key Players of IgG-Based Antibodies
Table 4. Global Bi-Specific Antibodies Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Bi-Specific Antibodies Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Bi-Specific Antibodies Therapy Market Size by Region (US$ Million), 2021–2026
Table 7. Global Bi-Specific Antibodies Therapy Market Share by Region (2021–2026)
Table 8. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Bi-Specific Antibodies Therapy Market Share by Region (2027–2032)
Table 10. Bi-Specific Antibodies Therapy Market Trends
Table 11. Bi-Specific Antibodies Therapy Market Drivers
Table 12. Bi-Specific Antibodies Therapy Market Challenges
Table 13. Bi-Specific Antibodies Therapy Market Restraints
Table 14. Global Bi-Specific Antibodies Therapy Revenue by Players (US$ Million), 2021–2026
Table 15. Global Bi-Specific Antibodies Therapy Market Share by Players (2021–2026)
Table 16. Global Top Bi-Specific Antibodies Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on Bi-Specific Antibodies Therapy Revenue, 2025
Table 17. Ranking of Global Top Bi-Specific Antibodies Therapy Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Bi-Specific Antibodies Therapy Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Bi-Specific Antibodies Therapy, Headquarters and Area Served
Table 20. Global Key Players of Bi-Specific Antibodies Therapy, Products and Applications
Table 21. Global Key Players of Bi-Specific Antibodies Therapy, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Bi-Specific Antibodies Therapy Market Size by Type (US$ Million), 2021–2026
Table 24. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2021–2026)
Table 25. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type (2027–2032)
Table 27. Global Bi-Specific Antibodies Therapy Market Size by Application (US$ Million), 2021–2026
Table 28. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2021–2026)
Table 29. Global Bi-Specific Antibodies Therapy Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2027–2032)
Table 31. North America Bi-Specific Antibodies Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Bi-Specific Antibodies Therapy Market Size by Country (US$ Million), 2021–2026
Table 33. North America Bi-Specific Antibodies Therapy Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Bi-Specific Antibodies Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Bi-Specific Antibodies Therapy Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Bi-Specific Antibodies Therapy Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Bi-Specific Antibodies Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Bi-Specific Antibodies Therapy Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Bi-Specific Antibodies Therapy Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Bi-Specific Antibodies Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country (US$ Million), 2027–2032
Table 46. Roche Company Details
Table 47. Roche Business Overview
Table 48. Roche Bi-Specific Antibodies Therapy Product
Table 49. Roche Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 50. Roche Recent Development
Table 51. Amgen Company Details
Table 52. Amgen Business Overview
Table 53. Amgen Bi-Specific Antibodies Therapy Product
Table 54. Amgen Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 55. Amgen Recent Development
Table 56. Sanofi Company Details
Table 57. Sanofi Business Overview
Table 58. Sanofi Bi-Specific Antibodies Therapy Product
Table 59. Sanofi Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 60. Sanofi Recent Development
Table 61. Pfizer Company Details
Table 62. Pfizer Business Overview
Table 63. Pfizer Bi-Specific Antibodies Therapy Product
Table 64. Pfizer Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 65. Pfizer Recent Development
Table 66. Johnson & Johnson Company Details
Table 67. Johnson & Johnson Business Overview
Table 68. Johnson & Johnson Bi-Specific Antibodies Therapy Product
Table 69. Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 70. Johnson & Johnson Recent Development
Table 71. AstraZeneca Company Details
Table 72. AstraZeneca Business Overview
Table 73. AstraZeneca Bi-Specific Antibodies Therapy Product
Table 74. AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 75. AstraZeneca Recent Development
Table 76. AbbVie Company Details
Table 77. AbbVie Business Overview
Table 78. AbbVie Bi-Specific Antibodies Therapy Product
Table 79. AbbVie Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 80. AbbVie Recent Development
Table 81. Lindis Biotech Company Details
Table 82. Lindis Biotech Business Overview
Table 83. Lindis Biotech Bi-Specific Antibodies Therapy Product
Table 84. Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 85. Lindis Biotech Recent Development
Table 86. MacroGenics, Inc Company Details
Table 87. MacroGenics, Inc Business Overview
Table 88. MacroGenics, Inc Bi-Specific Antibodies Therapy Product
Table 89. MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 90. MacroGenics, Inc Recent Development
Table 91. Genmab Company Details
Table 92. Genmab Business Overview
Table 93. Genmab Bi-Specific Antibodies Therapy Product
Table 94. Genmab Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 95. Genmab Recent Development
Table 96. Alphamab Co. Ltd Company Details
Table 97. Alphamab Co. Ltd Business Overview
Table 98. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product
Table 99. Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 100. Alphamab Co. Ltd Recent Development
Table 101. Akeso, Inc. Company Details
Table 102. Akeso, Inc. Business Overview
Table 103. Akeso, Inc. Bi-Specific Antibodies Therapy Product
Table 104. Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (US$ Million), 2021–2026
Table 105. Akeso, Inc. Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
Table 109. Authors List of This Report
List of Figures
Figure 1. Bi-Specific Antibodies Therapy Picture
Figure 2. Global Bi-Specific Antibodies Therapy Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Bi-Specific Antibodies Therapy Market Share by Type: 2025 vs 2032
Figure 4. Fragment-Based Antibodies Features
Figure 5. IgG-Based Antibodies Features
Figure 6. Global Bi-Specific Antibodies Therapy Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Bi-Specific Antibodies Therapy Market Share by Application: 2025 vs 2032
Figure 8. Cancer Case Studies
Figure 9. Haemophilia Case Studies
Figure 10. Other Non-Cancer Diseases Case Studies
Figure 11. Bi-Specific Antibodies Therapy Report Years Considered
Figure 12. Global Bi-Specific Antibodies Therapy Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 13. Global Bi-Specific Antibodies Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Bi-Specific Antibodies Therapy Market Share by Region: 2025 vs 2032
Figure 15. Global Bi-Specific Antibodies Therapy Market Share by Players in 2025
Figure 16. Global Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Bi-Specific Antibodies Therapy Revenue in 2025
Figure 18. North America Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 19. North America Bi-Specific Antibodies Therapy Market Share by Country (2021–2032)
Figure 20. United States Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Canada Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Bi-Specific Antibodies Therapy Market Share by Country (2021–2032)
Figure 24. Germany Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. France Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. U.K. Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Italy Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Russia Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Ireland Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Bi-Specific Antibodies Therapy Market Share by Region (2021–2032)
Figure 32. China Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Japan Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. South Korea Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Southeast Asia Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. India Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Australia & New Zealand Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Bi-Specific Antibodies Therapy Market Share by Country (2021–2032)
Figure 40. Mexico Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Brazil Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Bi-Specific Antibodies Therapy Market Share by Country (2021–2032)
Figure 44. Israel Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Saudi Arabia Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. UAE Bi-Specific Antibodies Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Roche Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 48. Amgen Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 49. Sanofi Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 50. Pfizer Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 51. Johnson & Johnson Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 52. AstraZeneca Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 53. AbbVie Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 54. Lindis Biotech Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 55. MacroGenics, Inc Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 56. Genmab Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 57. Alphamab Co. Ltd Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 58. Akeso, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2021–2026)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
